Outcomes following neoadjuvant chemotherapy: converting trial results into "real world" practice
Association of Breast Surgery ePoster Library. Pieri A. 05/15/17; 166244; P165
Andrew Pieri
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Rate & Comment (0)
Introduction: Neoadjuvant chemotherapy is now established in the management of breast cancer. This change in practice is based on the results of large clinical trials demonstrating the benefits of down staging the tumour. The aim of this study was to ascertain is these results could be achieved in everyday clinical practice.
Methods: Data was collected retrospectively from a single institution's pathology database. All patients who had undergone NACT between October 2013 and October 2015 were included.
Results: A total of 47 patients had NACT over the two year period. The indication for NACT was: to downstage tumours to permit breast conserving surgery (BCS) in 37 (79%) cases, locally advanced disease in 8 (17%), facilitate immediate reconstruction in 1 (2%) case and to allow time for genetic testing in 1 (2%) case. Table 1 shows pathological response rates categorised by receptor status. Of those who received NACT for down staging from obligated mastectomy, 23 (62%) successfully underwent BCS.
Conclusions: Pathological response rates in this study are relatively consistent with those published in recent major trials. We have shown a high rate of successful down staging patients from mastectomy to BCS. This study demonstrates the 'real world' benefits of giving chemotherapy in the neoadjuvant setting where indicated.
Methods: Data was collected retrospectively from a single institution's pathology database. All patients who had undergone NACT between October 2013 and October 2015 were included.
Results: A total of 47 patients had NACT over the two year period. The indication for NACT was: to downstage tumours to permit breast conserving surgery (BCS) in 37 (79%) cases, locally advanced disease in 8 (17%), facilitate immediate reconstruction in 1 (2%) case and to allow time for genetic testing in 1 (2%) case. Table 1 shows pathological response rates categorised by receptor status. Of those who received NACT for down staging from obligated mastectomy, 23 (62%) successfully underwent BCS.
Conclusions: Pathological response rates in this study are relatively consistent with those published in recent major trials. We have shown a high rate of successful down staging patients from mastectomy to BCS. This study demonstrates the 'real world' benefits of giving chemotherapy in the neoadjuvant setting where indicated.
Introduction: Neoadjuvant chemotherapy is now established in the management of breast cancer. This change in practice is based on the results of large clinical trials demonstrating the benefits of down staging the tumour. The aim of this study was to ascertain is these results could be achieved in everyday clinical practice.
Methods: Data was collected retrospectively from a single institution's pathology database. All patients who had undergone NACT between October 2013 and October 2015 were included.
Results: A total of 47 patients had NACT over the two year period. The indication for NACT was: to downstage tumours to permit breast conserving surgery (BCS) in 37 (79%) cases, locally advanced disease in 8 (17%), facilitate immediate reconstruction in 1 (2%) case and to allow time for genetic testing in 1 (2%) case. Table 1 shows pathological response rates categorised by receptor status. Of those who received NACT for down staging from obligated mastectomy, 23 (62%) successfully underwent BCS.
Conclusions: Pathological response rates in this study are relatively consistent with those published in recent major trials. We have shown a high rate of successful down staging patients from mastectomy to BCS. This study demonstrates the 'real world' benefits of giving chemotherapy in the neoadjuvant setting where indicated.
Methods: Data was collected retrospectively from a single institution's pathology database. All patients who had undergone NACT between October 2013 and October 2015 were included.
Results: A total of 47 patients had NACT over the two year period. The indication for NACT was: to downstage tumours to permit breast conserving surgery (BCS) in 37 (79%) cases, locally advanced disease in 8 (17%), facilitate immediate reconstruction in 1 (2%) case and to allow time for genetic testing in 1 (2%) case. Table 1 shows pathological response rates categorised by receptor status. Of those who received NACT for down staging from obligated mastectomy, 23 (62%) successfully underwent BCS.
Conclusions: Pathological response rates in this study are relatively consistent with those published in recent major trials. We have shown a high rate of successful down staging patients from mastectomy to BCS. This study demonstrates the 'real world' benefits of giving chemotherapy in the neoadjuvant setting where indicated.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}